MDF is also happy to help you understand whether something is in a legitimate clinical trial, an approved therapy…or not.
Important review articles on disease mechanisms of and therapy development for DM have recently been published.
The UK DM Patient Registry reports on disease burden for 556 patients with a confirmed diagnosis of DM1.
MDF shares an update on program project grants from the NINDS.
A new DM1 mouse model, with postnatal expression of expanded CUG repeat RNA in the brain, implicates reduced MBNL1 and MBNL2 in the staging of pathological and functional changes.